logo
Plus   Neg
Share
Email

Dr. Reddy's Laboratories Enters Licensing Deal With Gilead Sciences For Remdesivir

Dr. Reddy's Laboratories Ltd. (RDY) announced that it has entered licensing deal with Gilead Sciences, Inc. (GILD) to register, manufacture and sell Gilead's antiviral drug Remdesivir for the treatment of COVID-19, in 127 countries including India.

Under non-exclusive licensing agreement, Dr. Reddy's will receive technology transfer from Gilead for manufacturing of Remdesivir. Dr. Reddy's would need to do manufacturing scale up and obtain regulatory approval for marketing of Remdesivir in respective countries.

In May, FDA has issued emergency use authorization for Gilead Science Inc's (GILD) antiviral drug Remdesivir to treat Covid-19.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Securities and Exchange Commission is investigating the circumstances around Eastman Kodak Co.'s (KODK) announcement of a $765 million government loan to make ingredients for Covid-19 drugs, the Wall Street Journal reported citing people familiar with the matter. The National Retail Federation or NRF said that conflicting economic data amid a resurgence in coronavirus cases has made it difficult to predict how steadily the U.S. economic recovery will continue. NRF Chief Economist Jack Kleinhenz noted that based on quarterly and monthly data, the U.S. economic recovery is continuing despite the elevated COVID-19 cases. Ford Motor Company (F) announced that Jim Hackett plans to retire as President and CEO. He will continue as a special advisor to the company through March of 2021. The company has named Jim Farley as new president and CEO. He will join the board of directors, effective Oct. 1. Farley joined Ford in...
Follow RTT